The Nation's First Equitech Ecosystem for Neuromedical Solutions
BluePrint MedTech Cycle 5 Solicitation for neuromedical device funding is closed. For more information on our program, process and 2025 solitications, please
Translate your early-stage ideas to first-in-human prototypes
NeuroTech Harbor is seeking high-potential, high-risk medical device solutions that focus on diagnosis, prevention, treatment, management, or delay of onset of a neurological condition. Whether you have an early-stage idea or an advanced proof-of-concept project, we help take it to the next level.
NeuroTech Harbor (NTH) is a partnership between Johns Hopkins University and Howard University, and projects to spend between $30-$50M to launch 45 new neurological health innovation projects over the next 5 years.
Neurotech Harbor is the Nation’s first Equitech ecosystem for neuromedical solutions. The Equitech approach supports inclusive medical technologies that are designed and developed to meet the diverse needs of all individuals, regardless of their abilities, disabilities, or cultural backgrounds. Inclusive medical technologies promote equity, accessibility, and inclusivity in healthcare.
Receive grant funding, mentorship, and world-class resources for your cutting edge medical device ideas
Funded by the NIH and founded by Johns Hopkins University and Howard University, NeuroTech Harbor works with innovators to accelerate the development of groundbreaking solutions that alleviate human suffering from neurological conditions
Work with leading medical device commercialization experts and entrepreneurs
NeuroTech Harbor is founded and led by seasoned scientists, engineers, and clinicians to guide translation of projects from bench to bedside. Once selected, innovators will be matched with a customized “Dream Team” of advisors who will guide and support you every step of the way.
At NeuroTech Harbor, we believe in the mission of equitech. The equitech philosophy is the belief that diversity of teams, leadership, and perspectives is a force multiplier to fuel innovation producing solutions accessible to all communities. We are committed to diversity and inclusion during early-stage translation as the first critical step towards creating long-term clinical and social impact.
